Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | SGK1 | O00141 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508903 | 0.84 | HTR6 (0.46) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL12067166 | 0.81 | HTR6 (0.44) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL15882311 | 0.78 | ACLY (0.50) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL1626536 | 0.75 | L3MBTL1 (0.42) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL3956139 | 0.75 | ACLY (0.51) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL6828482 | 0.75 | ACLY (0.48) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL12932804 | 0.75 | MCL1 (0.49) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL13677614 | 0.74 | HTR6 (0.44) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL1641772 | 0.73 | L3MBTL1 (0.43) | MCL1HTR6ACLYFPR2PROKR1 | |
| SCHEMBL388129 | 0.73 | L3MBTL1 (0.43) | MCL1HTR6ACLYFPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | MCL1 4311/4885HTR6 1373/4885ACLY 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.